Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA4 | P22748 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | BCL9 | O00512 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | TTPA | P49638 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537574 | 0.95 | ESR2 (0.42) | ESR2PTGS2MEN1KMT2ACA12 | |
| SCHEMBL1038871 | 0.94 | ESR2 (0.41) | ESR2PTGS2MEN1KMT2ACA12 | |
| SCHEMBL20486280 | 0.90 | BCL9 (0.34) | ESR2PTGS2CA12CA1CA2 | |
| SCHEMBL16250391 | 0.80 | ALDH1A1 (0.36) | MEN1KMT2AEGFRERBB2BCL9 | |
| SCHEMBL20377292 | 0.80 | PTPN7 (0.31) | — | |
| SCHEMBL3539485 | 0.79 | PTGS2 (0.45) | ESR2PTGS2CA12CA1CA2 | |
| SCHEMBL4953772 | 0.78 | KMT2A (0.44) | MEN1KMT2A | |
| SCHEMBL17337909 | 0.78 | KMT2A (0.48) | MEN1KMT2A | |
| SCHEMBL25495837 | 0.77 | KMT2A (0.43) | MEN1KMT2A | |
| SCHEMBL21049231 | 0.77 | KMT2A (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238882-A1 | Process for Preparing Nitrooxy Esters, Nitrooxy Thioesters Nitrooxy Carbonates and Nitrooxy Thiocarbinates, Intermediates Useful in Said Process and Preparation Thereof | NICOX S.A. (FR) | 2007-10-11 | — | — | US | claimed |
| CN-1984871-A | Process for preparing nitrooxy esters, nitrooxy thioesters, nitrooxy carbonates and nitrooxy thiocarbonates, intermediates useful in said process and preparation thereof | NICOX SA (FR) | 2007-06-20 | — | — | CN | claimed |
| EP-1778617-A1 | PROCESS FOR PREPARING NITROOXY ESTERS, NITROOXY THIOESTERS, NITROOXY CARBONATES AND NITROOXY THIOCARBONATES, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NicOx S.A. (FR) | 2007-05-02 | — | — | EP | claimed |
| WO-2006008196-A1 | PROCESS FOR PREPARING NITROOXY ESTERS, NITROOXY THIOESTERS, NITROOXY CARBONATES AND NITROOXY THIOCARBONATES, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NICOX S.A. (FR) | 2006-01-26 | — | — | WO | claimed |
| CN-108349911-B | Nitric oxide releasing prodrug molecules | 浙江华海药业股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-10-29 | — | — | US | disclosed |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2018-09-06 | — | — | US | disclosed |
| EP-3348548-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| EP-2118120-B1 | NITRIC OXIDE RELEASING STEROIDS | NICOX SA (FR) | 2016-10-05 | — | — | EP | disclosed |
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20150105547-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. (FR) | 2015-04-16 | — | — | US | disclosed |
| US-8933062-B2 | Nitric oxide releasing steroids | NICOX S.A. (FR) | 2015-01-13 | — | — | US | disclosed |
| EP-1778617-A1 | PROCESS FOR PREPARING NITROOXY ESTERS, NITROOXY THIOESTERS, NITROOXY CARBONATES AND NITROOXY THIOCARBONATES, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NicOx S.A. (FR) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007045551-A2 | RENIN INHIBITORS NITRODERIVATIVES | NICOX S.A. (FR) | 2007-04-26 | — | — | WO | disclosed |
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | NICOX S.A. (FR) | 2006-12-07 | — | — | US | disclosed |
| CN-1832742-A | Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular diseases | NICOX SA (FR) | 2006-09-13 | — | — | CN | disclosed |
| WO-2006079610-A1 | NITROOXY SARTAN DERIVATIVES AS ANGIOTENSIN II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES | NICOX S.A. (FR) | 2006-08-03 | — | — | WO | disclosed |
| EP-1653950-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nicox S.A. (FR) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006008196-A1 | PROCESS FOR PREPARING NITROOXY ESTERS, NITROOXY THIOESTERS, NITROOXY CARBONATES AND NITROOXY THIOCARBONATES, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NICOX S.A. (FR) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005011646-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105547-A1 | NITRIC OXIDE RELEASING STEROIDS | NR3C1, CYP11B1, NOS1 | ESR2 212/4885PTGS2 121/4885MEN1 1142/4885 |
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | PTGIS, NOS1, NOS2 | ESR2 3881/4885PTGS2 23/4885MEN1 3887/4885 |
| US-20070238882-A1 | Process for Preparing Nitrooxy Esters, Nitrooxy Thioesters Nitrooxy Carbonates and Nitrooxy Thiocarbinates, Intermediates Useful in Said Process and Preparation Thereof | OTUB1, TET1, TET3 | ESR2 3446/4885PTGS2 660/4885MEN1 3860/4885 |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | NOS1, NOS2, PTGIS | ESR2 2294/4885PTGS2 16/4885MEN1 3406/4885 |
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | AGTR2, AGTR1, REN | ESR2 107/4885PTGS2 359/4885MEN1 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.